trending Market Intelligence /marketintelligence/en/news-insights/trending/4uyveio3-bozvc5ze3y6fg2 content esgSubNav
In This List

Verastem chief medical officer resigns, director appointed

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Verastem chief medical officer resigns, director appointed

Verastem Inc., which operates as Verastem Oncology, said NgocDiep Le resigned as chief medical officer to pursue other opportunities.

He was appointed in October 2017.

Hagop Youssoufian will replace Le, moving from his current role as head of hematology and oncology development.

In addition, the company said S. Louise Phanstiel resigned as director and Gina Consylman was appointed to replace Phanstiel, effective Oct. 18.

Consylman currently serves as senior vice president and CFO of Ironwood Pharmaceuticals Inc., a commercial biotech company.

Needham, Mass.-based Verastem focuses on developing cancer drugs. It recently granted Hong Kong-listed CSPC Pharmaceutical Group Ltd exclusive license to develop and market its cancer drug Copiktra for all oncology indications in China.